Request the brochure

* Denotes Required Field
Theme: Promoting Biologics Drug Development in China at Lower Cost, Higher Speed and Superior Quality
Riding on the success of the meeting last year, Biologics Innovation and Frontier Technology (BIFT 2017) is the definitive conference in China for receiving first-hand information on the current international status of the Biopharmaceutical industry and China’s biopharmaceutical opportunities, bringing together decision makers across C level management, R&D and Manufacturing in the realms of biologic drugs, biosimilars, biotech and Immuno-oncology sectors. This two day interactive meeting will provide you the opportunity to take home cutting edge strategies, case study examples, regulatory guidelines with rich information on the latest innovations, strategy, pipeline, partnership and exciting candidates from leading biopharmas in China; case studies on cell lines and process development, scale-up and downstream innovations, single-use technology; evaluation and quality of biosimilars, frontier technology in biologics development etc. We welcome you to the meeting to establish and renew partnerships to help develop new products, acquire new process technologies, and establish new contract manufacturing relationships. Read more...

Event Features

  • 300+ delegates from over 10 countries and regions
  • 100+ attending organizations
  • 40+ eminent biopharma, biotech and biomanufacturing speakers
  • 70% on average attendees from primary and end user market (biopharma, biot
  • 60% above company decision making and director level
  • 1 main conference and 4 focused streams

Leverage BIFT China 2017 to Gain Insights and Solutions of

  • The current status of MAH, clinical drug investigation, process development etc, in China
  • The frontier technologies, quality standards and practices in mAb, PD-1. ADC and bispecific antibody development
  • Pre-clinical and clinical challenges associated with the development of biosimilars
  • Challenges encountered with assessing immunogenicity and pharmacovigilance
  • CMC challenges and considerations for biologics drug development and manufacturing
  • The best practice of smart factory design and continuous processing
  • Innovative technologies of biologics manufacturing process in China
  • Key successful factors for partnerships and collaboration for biologics and biosimilar product development in Asia
Produced by
Media Partners